GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shield Therapeutics PLC (LSE:STX) » Definitions » Pre-Tax Income

Shield Therapeutics (LSE:STX) Pre-Tax Income : £-37.21 Mil (TTM As of Jun. 2023)


View and export this data going back to 2016. Start your Free Trial

What is Shield Therapeutics Pre-Tax Income?

Pretax income is the income that a company earns before paying income taxes. Shield Therapeutics's pretax income for the six months ended in Jun. 2023 was £-11.79 Mil. Its pretax income for the trailing twelve months (TTM) ended in Jun. 2023 was £-37.21 Mil. Shield Therapeutics's pretax margin was -272.10%.

During the past 9 years, Shield Therapeutics's highest Pretax Margin was -18.16%. The lowest was -5132.57%. And the median was -1260.92%.


Shield Therapeutics Pre-Tax Income Historical Data

The historical data trend for Shield Therapeutics's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shield Therapeutics Pre-Tax Income Chart

Shield Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Pre-Tax Income
Get a 7-Day Free Trial Premium Member Only -5.15 -9.07 -1.89 -19.91 -40.08

Shield Therapeutics Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Pre-Tax Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -7.58 -12.32 -14.66 -25.42 -11.79

Competitive Comparison of Shield Therapeutics's Pre-Tax Income

For the Drug Manufacturers - Specialty & Generic subindustry, Shield Therapeutics's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shield Therapeutics's Pre-Tax Income Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Shield Therapeutics's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where Shield Therapeutics's Pre-Tax Income falls into.



Shield Therapeutics Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

Shield Therapeutics's Pretax Income for the fiscal year that ended in Dec. 2022 is calculated as

Pretax Income=Operating Income+Non Operating Income+Interest Expense+Interest Income+Other
=-25.707+0+-0.327+0.03+-14.078
=-40.08

Shield Therapeutics's Pretax Income for the quarter that ended in Jun. 2023 is calculated as

Pretax Income=Operating Income+Non Operating Income+Interest Expense+Interest Income+Other
=-11.541+0+-0.578+0.326+0
=-11.79

Pre-Tax Income for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was £-37.21 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Shield Therapeutics  (LSE:STX) Pre-Tax Income Explanation

Shield Therapeutics's Pretax Margin for the quarter that ended in Jun. 2023 is calculated as

Pretax Margin=Pretax Income/Revenue
=-11.793/4.334
=-272.10%

During the past 9 years, Shield Therapeutics's highest Pretax Margin was -18.16%. The lowest was -5132.57%. And the median was -1260.92%.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Shield Therapeutics Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of Shield Therapeutics's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Shield Therapeutics (LSE:STX) Business Description

Traded in Other Exchanges
Address
Northern Design Centre, Baltic Business Quarter, Gateshead Quays, Newcastle, GBR, NE8 3DF
Shield Therapeutics PLC is a specialty pharmaceutical company focused on the development and commercialization of late-stage, hospital-focused pharmaceuticals which address areas of high unmet medical need. The company's operating segments are based on key products including Accrufer/Feraccru, used as a novel oral treatment for iron deficiency anemia in patients, which is commercially available, and PT20 used in treating hyperphosphatemia, which is in its last stage of completion. The company generates maximum revenue from Feraccru segment.